Preclinical Modeling Equipment & Supplies
99 equipment items found
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent ...
by:CohBar, Inc. based inMenlo Park, CALIFORNIA (USA)
Is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP) that plays a key role in regulating metabolism. Has resulted in significant impacts on NASH and obesity in multiple preclinical models. Has been shown in a clinical study to significantly reduce ALT and AST, key biomarkers of liver damage, as well as glucose levels ...
Manufactured by:Altimmune Inc. based inGaithersburg, MARYLAND (USA)
Because ALT-801 acts across these multiple pathways, it may be able to correct the metabolic dysfunction at the heart of NASH as demonstrated in one of the best preclinical models of the disease. ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
The SPOR COV™ product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. SPOR-COV™ has already been shown by SporeGen to provide complete (100%) protection in preclinical models of ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology to knockdown the expression of NKG2D ligands MICA ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Targeted and selective inhibition of SIK proteins brings an opportunity to restore the immune balance that is typically out of balance in autoimmune diseases. .We have observed encouraging activity in various inflammatory preclinical models with compounds targeting this ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC399 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP), intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration. A Phase I/II ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models.3 Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new ...
Manufactured by:GENFIT based inLoos, FRANCE
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept clinical trial for the potential ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis. ...
Manufactured by:multimmune GmbH based inMunich, GERMANY
In vivo application of ENKASTIM-iv, an Hsp70-based GMP-grade synthetic peptide comprising 14 amino acids (14mer), results in a specific activation of NK cells which acquire the capacity to recognise and kill membrane Hsp70-positive tumors and ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-0184 is an investigational inhibitor of activin receptor-like kinase 2 (ALK2) and ALK5 (also known as TGFβR1). This bimodal inhibitor is believed to downregulate multiple TGF-β superfamily signaling pathways and has shown antitumor activity in several ...
Manufactured by:Elpiscience based inShanghai, CHINA
OX40, also known as CD134, is a member of the tumor necrosis factor (TNF) receptor family and is an important co-stimulator of T cell responses. Typically for TNF receptor family members, 3 molecules of OX40 bind to the trimeric OX40 ligand-protein, activating downstream NF-κB, PI3K, and AKT pathways, which lead to increased cytokine production. Activation of OX40 enhances T-cell expansion, ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Many of the childhood-onset intractable epilepsy conditions within the expanded access program share considerable overlap with ASD and these conditions often fall within the orphan disease space. Initial clinical observations from treating physicians suggest a potential role for cannabinoids in addressing problems associated with ASD such as deficits in cognition, behavior, and ...
Manufactured by:EPED Inc. based inKaohsiung City, TAIWAN
The Most Flexible Augmented-Reality Simulator in Dental Clinical Training Education. SimEx is the most adaptive Augmented-Reality Simulator currently in today’s marketplace, enabling any dental school to select what typodont to use,and to customize the technology to their school’s speciï¬c ...
by:Micro Photonics Inc. based inAllentown, PENNSYLVANIA (USA)
Radiation exposure of researchers is blocked with internal protection, making the InAlyzer safe, effective, and accurate for use in the preclinical research phase. Optional model: For mid-sized laboratory animals such as rabbits and guinea pigs, Save time, cost, and animals, Automated, accurate, and precise measurement, High resolution images ...
Manufactured by:Adrenomed AG based inBerlin, GERMANY
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular ...